| Quarter | Score |
|---|---|
| 2023-Q3 | 50.1 |
| 2023-Q4 | 65.6 |
| 2024-Q1 | 49.7 |
| 2024-Q2 | 51.6 |
| 2024-Q3 | 87.4 |
| 2024-Q4 | 77.6 |
| 2025-Q1 | 61.4 |
| 2025-Q2 | 79.0 |
| 2025-Q3 | 80.2 |
| 2025-Q4 | 66.1 |
| 2026-Q1 | 68.3 |
| 2026-Q2 | 77.0 |
Strong consensus, but price is extended — wait for pullback to funds' basis
Trading +51.1% above funds' purchase price — elevated pullback risk
3 of 18 tracked funds hold LLYVA. Avg conviction: 0.5%. Net holding. First tracked at $62.76 (current +51.1% vs tracked).
ValueAct Capital has 1.4% in this stock
Prices are approximate, based on 13F reported values (position value / shares), not actual cost basis. Data covers 17 tracked value-oriented funds. Holdings are reported quarterly with a ~45-day lag. Stock splits may affect share count comparisons. Returns are not annualized.
| Fund | % of Portfolio | Action |
|---|---|---|
| ValueAct Capital | 1.4% | Reduce |
| Berkshire Hathaway | 0.2% | Hold |
| Citadel Advisors | 0.0% | New Buy |